PL3130353T3 - Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych - Google Patents

Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych

Info

Publication number
PL3130353T3
PL3130353T3 PL15774194T PL15774194T PL3130353T3 PL 3130353 T3 PL3130353 T3 PL 3130353T3 PL 15774194 T PL15774194 T PL 15774194T PL 15774194 T PL15774194 T PL 15774194T PL 3130353 T3 PL3130353 T3 PL 3130353T3
Authority
PL
Poland
Prior art keywords
preventing
pharmaceutical composition
neurodegenerative diseases
treating neurodegenerative
based pharmaceutical
Prior art date
Application number
PL15774194T
Other languages
English (en)
Inventor
Byung Hee Hong
Je Min Yoo
Hanseok Ko
Donghoon Kim
Original Assignee
Seoul National University R&Db Foundation
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University R&Db Foundation, The Johns Hopkins University filed Critical Seoul National University R&Db Foundation
Publication of PL3130353T3 publication Critical patent/PL3130353T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/15—Nano-sized carbon materials
    • C01B32/182—Graphene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B2204/00—Structure or properties of graphene
    • C01B2204/20—Graphene characterized by its properties
    • C01B2204/32—Size or surface area

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Nanotechnology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
PL15774194T 2014-04-04 2015-04-03 Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych PL3130353T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20140040400 2014-04-04
EP15774194.3A EP3130353B1 (en) 2014-04-04 2015-04-03 Graphene nanostructure-based pharmaceutical composition for preventing or treating neurodegenerative diseases
PCT/KR2015/003385 WO2015152688A1 (ko) 2014-04-04 2015-04-03 퇴행성 신경 질환의 예방 또는 치료를 위한 그래핀 나노구조체 기반 약학적 조성물

Publications (1)

Publication Number Publication Date
PL3130353T3 true PL3130353T3 (pl) 2021-03-08

Family

ID=54240900

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15774194T PL3130353T3 (pl) 2014-04-04 2015-04-03 Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych

Country Status (8)

Country Link
US (2) US20170189359A1 (pl)
EP (1) EP3130353B1 (pl)
JP (1) JP6585156B2 (pl)
KR (1) KR101747147B1 (pl)
CN (2) CN113018437A (pl)
ES (1) ES2814274T3 (pl)
PL (1) PL3130353T3 (pl)
WO (1) WO2015152688A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3714891B1 (en) * 2017-11-24 2024-02-14 Seoul National University R&DB Foundation Anti-inflammatory composition comprising graphene nano-structure
WO2020009551A1 (ko) * 2018-07-06 2020-01-09 바이오그래핀 주식회사 신경단백질의 비정상적 섬유화 또는 응집과 관련된 질환 치료제로서의 그래핀 양자점
JP7266800B2 (ja) * 2018-07-06 2023-05-01 バイオグラフェン インコーポレイテッド 神経タンパク質の異常な線維化または凝集に関連する疾患治療剤としてのグラフェン量子ドット
EP3597594A1 (en) 2018-07-17 2020-01-22 Graphenano Medical Care, S.L. Graphene product and therapeutic uses thereof
KR102179430B1 (ko) * 2019-01-30 2020-11-16 바이오그래핀 주식회사 리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물
CN110251532B (zh) * 2019-07-18 2022-04-15 苏州大学 碳基纳米材料在制备缓解或者治疗hd药物中的应用
KR102277665B1 (ko) * 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
CN112089731A (zh) * 2020-09-29 2020-12-18 安徽医科大学第一附属医院 纳米氧化石墨烯在β淀粉样蛋白Aβ相关疾病治疗中的应用及其试验方法
CN112552902A (zh) * 2020-11-20 2021-03-26 扬州大学 一种泡沫结构的石墨烯量子点组装体及其制备方法
CN116327934A (zh) * 2023-03-30 2023-06-27 北京理工大学 一种抗β淀粉样蛋白聚集的紫磷@核酸适体纳米片的制备方法和应用
WO2024248251A1 (ko) * 2023-05-30 2024-12-05 그래핀스퀘어케미칼 주식회사 그래핀 양자점을 유효성분으로 포함하는 퇴행성 신경 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688299A (zh) * 2002-01-29 2005-10-26 普罗特米克斯公司 抑制细胞毒性蛋白构象异构体
US7163956B2 (en) * 2003-10-10 2007-01-16 C Sixty Inc. Substituted fullerene compositions and their use as antioxidants
CN101267779A (zh) * 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
GB2432529B (en) 2005-11-25 2008-04-23 Univ Feng Chia Antimicrobial compositions and wound dressings
JP2009537179A (ja) 2006-05-19 2009-10-29 ザ スクリップス リサーチ インスティテュート 蛋白質ミスフォールディングの処置
US9572834B2 (en) * 2011-04-26 2017-02-21 William Marsh Rice University Use of carbon nanomaterials with antioxidant properties to treat oxidative stress
WO2013148341A1 (en) * 2012-03-27 2013-10-03 Duke University Carbon nanotubes and methods of use
KR102020870B1 (ko) * 2012-04-30 2019-09-16 바이오그래핀 주식회사 그래핀 양자점 또는 산화그래핀 양자점을 포함하는 mri 조영제, 및 그 제조방법
US10114024B2 (en) 2013-08-28 2018-10-30 Nanyang Technological University Biomolecule-graphene quantum dot conjugates and use thereof
US20160193249A1 (en) * 2013-09-03 2016-07-07 William Marsh Rice University Treatment of inflammatory diseases by carbon materials

Also Published As

Publication number Publication date
US20170189359A1 (en) 2017-07-06
JP6585156B2 (ja) 2019-10-02
KR101747147B1 (ko) 2017-06-14
CN113018437A (zh) 2021-06-25
JP2017510650A (ja) 2017-04-13
EP3130353B1 (en) 2020-07-22
US20180289646A1 (en) 2018-10-11
ES2814274T3 (es) 2021-03-26
US10772910B2 (en) 2020-09-15
EP3130353A4 (en) 2017-11-15
EP3130353A1 (en) 2017-02-15
CN106470706A (zh) 2017-03-01
WO2015152688A1 (ko) 2015-10-08
KR20150115671A (ko) 2015-10-14

Similar Documents

Publication Publication Date Title
IL268316B (en) Pharmaceutical preparations for combined treatment
ZA201706007B (en) Pharmaceutical compositions for combination therapy
IL247003A0 (en) Isoindoline compounds and methods for the treatment of neurodegenerative diseases
SG11201705093UA (en) Composition for treating il-6-related diseases
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
IL249231A0 (en) Pharmaceutical combinations for cancer treatment
EP3104706A4 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
EP3130353A4 (en) Graphene nanostructure-based pharmaceutical composition for preventing or treating neurodegenerative diseases
EP3157631A4 (en) Neurodegenerative disease treatment
ZA201607729B (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
PL3129378T3 (pl) Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu
SG11201705194XA (en) Pharmaceutical composition for treating diabetes
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
PL3236961T3 (pl) Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego
EP3148570A4 (en) Pharmaceutical composition for preventing or treating skin rash
IL249440B (en) Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases
ZA201500995B (en) Low dose pharmaceutical composition
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
IL246919A0 (en) New preparations for the treatment of mechanical nerve injuries
GB201420348D0 (en) Compounds for treating neurodegenerative diseases
IL236381A0 (en) Pharmaceutical preparations for the treatment of cancer
HK1232777A1 (en) New compositions for treating mechanical neuronal injuries
HK1236134A1 (en) Pharmaceutical combination for the treatment of cancer
AU2014902366A0 (en) Neurodegenerative disease treatment